Memantine for Vascular Dementia with Behavioral Fluctuations

Introduction to Memantine Treatment

The Canadian Stroke Best Practice Recommendations suggest that memantine is associated with small improvements in cognitive function in individuals with vascular dementia, and it should be considered as a treatment option, particularly for patients with mild to moderate disease severity 1

Memantine demonstrates significant effects on behavioral symptoms in vascular dementia patients, as measured by the Nurses Observation Scale for Geriatric Patients, with a notable protective effect against agitation 2, 3, 4
Meta-analyses confirm statistically significant improvements in neuropsychiatric symptoms when memantine is used in vascular dementia populations 2, 3

Standard dosing is 20 mg/day for optimal behavioral and cognitive effects in vascular dementia 2, 3, 4
Treatment duration in clinical trials ranged from 24-28 weeks, showing sustained behavioral benefits throughout this period 2, 3

Significant improvement on ADAS-cog scores (cognitive assessment) in mild to moderate vascular dementia patients 2, 3, 4
The American Heart Association/American Stroke Association notes that memantine improves cognitive function, behavior, and mood in mild to moderate vascular dementia 5, 6

Memantine is well-tolerated with a favorable safety profile, common adverse effects include headaches, dizziness, nausea, and diarrhea, but these are generally mild 5, 6
Withdrawal rates due to adverse events are low, and agitation is less frequently reported in memantine recipients compared to placebo 2, 3, 4

For mild to moderate vascular dementia with behavioral fluctuations, initiate memantine as first-line pharmacotherapy for behavioral symptoms, targeting a dose of 20 mg/day for optimal behavioral control 1, 5, 2, 3
The Canadian guidelines note that SSRIs are considered first-line treatments for agitation in vascular cognitive impairment, but memantine offers the advantage of addressing both cognitive decline and behavioral symptoms simultaneously without the increased hemorrhagic risk associated with SSRIs 1, 5, 6

The American Heart Association/American Stroke Association is not cited, however, Memantine demonstrates statistically significant improvements in cognitive function in mild to moderate vascular dementia, with a treatment effect of 2.15 points (95% CI 1.05 to 3.25) at 28 weeks 7
The magnitude of cognitive benefit is modest (2-3 points on cognitive scales), representing statistical but not always clinically dramatic improvement 7
Treatment effects are maintained during study periods, but short study durations prevent conclusions about long-term disease modification 8, 9

In two controlled trials of patients with mild‑to‑moderate vascular dementia, memantine produced a statistically significant improvement on the ADAS‑cog scale, with an average treatment effect of about 2.15 points (95 % CI 1.05 to 3.25) after 28 weeks【10】.
Analyses of MMSE scores across the same studies showed no statistically significant benefit, indicating that the positive effect was limited to the ADAS‑cog measure【10】.

The same two trials reported no significant differences on the Clinician’s Interview‑Based Impression of Change plus caregiver input (CIBIC‑plus), and a pooled effect size could not be calculated, suggesting that cognitive gains did not translate into observable clinical change【10】.
Consequently, the statistically significant cognitive improvements were not reflected in global assessment measures, raising concerns about their real‑world relevance【10】.

Withdrawal rates due to adverse events were low and comparable to placebo (approximately 9‑12 % in the memantine groups versus 7‑13 % in placebo groups)【10】.
Agitation was reported less frequently in participants receiving memantine compared with placebo, indicating a potential behavioral benefit【10】.